Company Overview and News

3
Tetra Bio-Pharma Inc. Provides Corporate Update Ahead of Its Annual General Meeting

2018-06-13 globenewswire
ORLEANS, Ontario, June 13, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation”) (TSX VENTURE:TBP) (OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to provide a Corporate Update on its programs and upcoming milestones in the development of its bio-pharmaceutical and natural health products that address large markets with significant unmet medical needs.
TBPMF TBP GRPOF

3
Tetra Bio-Pharma Inc. Clarifies AGM Meeting Location

2018-05-17 globenewswire
ORLEANS, Ontario, May 17, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation”) (TSX VENTURE:TBP) (OTCQB:TBPMF), wishes to clarify that the annual general meeting of shareholders of the Corporation (the “Meeting”) is to be held in the City of Montréal, Québec. The Corporation noted that the notice of meeting and record date filed under the Corporation’s profile on SEDAR on April 27, 2018 incorrectly stated that the Meeting would be held in the City of Ottawa, Ontario.
TBPMF TBP GRPOF

3
Tetra BioPharma Signs Second Commercialization Deal with Azevedos Industria Farmaceutica, S.A. for the Lead RX product PPP001

2018-05-04 globenewswire
OTTAWA, May 04, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), and Azevedos Indústria Farmacêutica, S.A. announced that they have signed a binding term sheet for the marketing and distribution of PPP001 in Portugal. This binding term sheet will pave the way towards signing a Definitive Distribution Agreement.
TBPMF TBP GRPOF

30
Tetra Bio-Pharma Signs Landmark Commercialization Term Sheet for its Lead Pharmaceutical Product, PPP001, in Israel

2018-04-24 marketwired
OTTAWA, ONTARIO--(Marketwired - April 24, 2018) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP) (OTCQB:TBPMF), announced today that the Company has signed a first binding term sheet for the marketing and distribution of PPP001 in Israel with Kamada Ltd., a leading pharmaceutical company. The signing of a Definitive Distribution Agreement is expected to follow shortly. PPP001 is being developed to be the first smokable cannabis product for advanced cancer pain available under prescription.
TBPMF KMDA TBP GRPOF

9
Tetra Bio-Pharma Clinical Study on Cannabis Oil Capsules for Patients Suffering from Chronic Pain should be completed by Fall 2018

2018-04-12 marketwired
OTTAWA, ONTARIO--(Marketwired - April 12, 2018) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP) (OTCQB:TBPMF), provides a status report on its encapsulated cannabis oils (PPP005) clinical trials and that these cannabis products are ready to commercialize in the retail market post-legalization.
TBPMF APH APHQF TBP GRPOF

3
Tetra Bio-Pharma Announces the appointment of Gregory Drohan to its board of directors

2018-04-10 marketwired
OTTAWA, ONTARIO--(Marketwired - April 10, 2018) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, announced today that it has appointed Gregory Drohan to its board of directors effective April 10, 2018.
TBPMF TBP GRPOF

3
Tetra Bio-Pharma Initiates Enrolment of Patients in Phase 3 PPP001 Smokable Cannabis Pellet Study

2018-04-04 marketwired
OTTAWA, ONTARIO--(Marketwired - April 4, 2018) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP) (OTCQB:TBPMF), today announced the initiation of screening and enrolment activities in the Phase 3 study of its PPP001 smokable cannabis pellet for advanced cancer patients with uncontrolled pain.
TBPMF TBP GRPOF

3
Tetra Bio-Pharma Names Guy Chamberland as Interim CEO

2018-04-03 marketwired
OTTAWA, ONTARIO--(Marketwired - April 3, 2018) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced the appointment of Guy Chamberland, M.Sc., Ph.D., an accomplished drug developer, as interim Chief Executive Officer (CEO). This appointment is effective immediately.
TBPMF TBP GRPOF

3
CORRECTION FROM SOURCE: Tetra Bio-Pharma Inc. Announces the Closing of $4,292,000 Non-Brokered Private Placement

2018-03-28 marketwired
OTTAWA, ONTARIO--(Marketwired - March 27, 2018) - This document corrects and replaces the press release that was sent on March 27, 2018 at 7:30 PM ET.
TBPMF TBP GRPOF

3
Tetra Bio-Pharma Inc. Announces the Closing of $4,422,000 Non-Brokered Private Placement

2018-03-27 marketwired
OTTAWA, ONTARIO--(Marketwired - March 27, 2018) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce it has closed its non-brokered private placement of 4,422,000 units at a price of $1.00 per unit for aggregate gross proceeds of $4,422,000. Each unit consists of one common share and one non-transferable warrant, with a warrant entitling the holder to purchase one common share at a price of $1.
TBPMF TBP GRPOF

3
Tetra Bio-Pharma Added to Leading Cannabis ETF: Horizons Marijuana Life Sciences Index

2018-03-20 marketwired
OTTAWA, ONTARIO--(Marketwired - March 20, 2018) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has been added to the Horizons Marijuana Life Sciences Index (HMMJ) managed by Horizons ETFs Management (Canada) Inc.
TBPMF TBP GRPOF

3
Tetra Bio-Pharma Completes Acquisition of Remaining 20% Interest in PhytoPain Pharma Inc.

2018-03-19 marketwired
OTTAWA, ONTARIO--(Marketwired - March 19, 2018) - Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced the completion of the previously announced acquisition of the remaining 20% interest in its PhytoPain Pharma Inc. subsidiary (the "Transaction") from entities controlled by André Rancourt, Chairman of the Board of Directors of the Corporation, and Guy Chamberland, Chief Scientific Officer of the Corporation (collectively, the "Sellers").
TBPMF TBP GRPOF

3
Tetra Bio-Pharma Inc. Announces a Non-Brokered Private Placement

2018-03-16 marketwired
OTTAWA, ONTARIO--(Marketwired - March 16, 2018) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that it is conducting a non-brokered private placement of up to 4,500,000 units at a price of $1.00 per unit for aggregate gross proceeds of up to $4,500,000.
TBPMF TBP GRPOF

3
Tetra Bio-Pharma Announces FDA Orphan Drug Designation for PPP001 in Treatment of Complex Regional Pain Syndrome

2018-03-14 marketwired
OTTAWA, ONTARIO--(Marketwired - March 14, 2018) - Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the active ingredients of its PPP001 drug (delta-9-tetrahydrocannabinol 9.5% and cannabidiol 2.5%) for the treatment of complex regional pain syndrome (CRPS). The Orphan Drug Designation was granted for the active moiety of the drug PPP001 and not the formulation.
TBPMF TBP GRPOF

Related Articles

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

STML: Stemline Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...

CUSIP: 39985Y102